Ultra-low to Moderate Radiation Level Neutron Dosimetry Measurements with H*10-TMFD vs. ROSPEC, Eberline, and Ludlum Detector Systems.

H*10 neutron dosimetry (unlike gamma dosimetry), requires consideration of neutron energy spectra due to the 20× variation of the weight factor over the thermal-to-fast energy range, as well as the neutron radiation field dose rates ranging from cosmic, ~.01 μSv h-1 levels to commonly encountered ~10-200 μSv h-1 in nuclear laboratories/processing plants, and upwards of 104 Sv h-1 in nuclear reactor environments. This paper discusses the outcome of the comparison of spectrum-weighted neutron dosimetry covering thermal-to-fast energy using the novel H*-TMFD spectroscopy-enabled sensor system in comparison with measurements using state-of-the-art neutron dosimetry systems at SRNS-Rotating Spectrometer (ROSPEC), and non-spectroscopic Eberline ASP2E ("Eberline") and Ludlum 42-49B ("Ludlum") survey instrumentation.

Biology of extracellular vesicles and the potential of tumor-derived vesicles for subverting immunotherapy of cancer.

Extracellular vesicles (EVs) are produced by all living cells and are present in all body fluids. EVs are heterogeneous in size, biogenesis, molecular/genetic content and functions. They constitute a part of the intercellular communication system.

Expression of vesiculation-related genes is associated with a tumor-promoting microenvironment: a pan-cancer analysis.

Background: Small extracellular vesicles (sEV) released by tumor cells (tumor-derived sEV; TEX) mediate intercellular communication between tumor and non-malignant cells and were shown to impact disease progression. This study investigates the relationship between the expression levels of the vesiculation-related genes linked to sEV production and the tumor microenvironment (TME).

Methods: Two independent gene sets were analyzed, both previously linked to sEV production in various non-malignant or malignant cells.

Assessment of adenosinergic activity of small extracellular vesicles in plasma of cancer patients and healthy donors.

The adenosinergic pathway converting endogenous ATP to adenosine (ADO) is a major immunosuppressive pathway in cancer. Emerging data indicate that plasma small extracellular vesicles (sEV) express CD39 and CD73 and produce ADO. Using a noninvasive, highly sensitive newly developed assay, metabolism of N-etheno-labeled eATP, eADP or eAMP by ecto-nucleotidases on the external surface of sEV was measured using high pressure liquid chromatography with fluorescence detection.